TY - JOUR
T1 - Chronic exposure to a TLR ligand injures hematopoietic stem cells
AU - Esplin, Brandt L.
AU - Shimazu, Tomoyuki
AU - Welner, Robert S.
AU - Garrett, Karla P.
AU - Nie, Lei
AU - Zhang, Qingzhao
AU - Humphrey, Mary Beth
AU - Yang, Qi
AU - Borghesi, Lisa A.
AU - Kincade, Paul W.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Hematopoietic stem cells (HSC) can be harmed by disease, chemotherapy, radiation, and normal aging.We show in this study that damage also occurs in mice repeatedly treated with very low doses of LPS. Overall health of the animals was good, and there were relatively minor changes in marrow hematopoietic progenitors. However, HSC were unable to maintain quiescence, and transplantation revealed them to be myeloid skewed. Moreover, HSC from treated mice were not sustained in serial transplants and produced lymphoid progenitors with low levels of the E47 transcription factor. This phenomenon was previously seen in normal aging. Screening identified mAbs that resolve HSC subsets, and relative proportions of these HSC changed with age and/or chronic LPS treatment. For example, minor CD150HiCD48- populations lacking CD86 or CD18 expanded. Simultaneous loss of CD150Lo/-CD48- HSC and gain of the normally rare subsets, in parallel with diminished transplantation potential, would be consistent with age- or TLR-related injury. In contrast, HSC in old mice differed from those in LPS-treated animals with respect to VCAM-1 or CD41 expression and lacked proliferation abnormalities. HSC can be exposed to endogenous and pathogen-derived TLR ligands during persistent low-grade infections. This stimulation might contribute in part to HSC senescence and ultimately compromise immunity.
AB - Hematopoietic stem cells (HSC) can be harmed by disease, chemotherapy, radiation, and normal aging.We show in this study that damage also occurs in mice repeatedly treated with very low doses of LPS. Overall health of the animals was good, and there were relatively minor changes in marrow hematopoietic progenitors. However, HSC were unable to maintain quiescence, and transplantation revealed them to be myeloid skewed. Moreover, HSC from treated mice were not sustained in serial transplants and produced lymphoid progenitors with low levels of the E47 transcription factor. This phenomenon was previously seen in normal aging. Screening identified mAbs that resolve HSC subsets, and relative proportions of these HSC changed with age and/or chronic LPS treatment. For example, minor CD150HiCD48- populations lacking CD86 or CD18 expanded. Simultaneous loss of CD150Lo/-CD48- HSC and gain of the normally rare subsets, in parallel with diminished transplantation potential, would be consistent with age- or TLR-related injury. In contrast, HSC in old mice differed from those in LPS-treated animals with respect to VCAM-1 or CD41 expression and lacked proliferation abnormalities. HSC can be exposed to endogenous and pathogen-derived TLR ligands during persistent low-grade infections. This stimulation might contribute in part to HSC senescence and ultimately compromise immunity.
UR - http://www.scopus.com/inward/record.url?scp=79955530513&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955530513&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1003438
DO - 10.4049/jimmunol.1003438
M3 - Article
C2 - 21441445
AN - SCOPUS:79955530513
SN - 0022-1767
VL - 186
SP - 5367
EP - 5375
JO - Journal of Immunology
JF - Journal of Immunology
IS - 9
ER -